PTJ
PACB icon

Paul Tudor Jones’s Pacific Biosciences PACB Stock Holding History

Paul Tudor Jones’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,400
Closed -$231K – 2713
2023
Q2 		$231K Buy
+17,400
New +$211K ﹤0.01% 2150

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's PACB Position: Q2 2026 in Review

Paul Tudor Jones held its Pacific Biosciences (PACB) position steady in Q2 2026 at 684,707 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

Paul Tudor Jones first reported a position in PACB in Q1 2015 and has held it in 12 quarters since. The position peaked at $2.18M in Q2 2022. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Paul Tudor Jones held 684,707 shares of Pacific Biosciences worth $1.15M as of Q2 2026.
  • Paul Tudor Jones left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2317 holding.
  • Paul Tudor Jones first reported a position in Pacific Biosciences in Q1 2015 and has held it in 12 quarters since.
  • Paul Tudor Jones's Pacific Biosciences position peaked at $2.18M in Q2 2022.
  • 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.